Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Methylation Signature of Circulating Tumour DNA as a Prognostic and Theranostic Tool for Managing Pancreatic Ductal Adenocarcinoma

NCT07045571 is registered in ClinicalTrials.gov with Yingbin Liu, MD, PhD, FACS as lead sponsor.

NCT NCT07045571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07045571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Methylation Signature of Circulating Tumour DNA as a Prognostic and Theranostic Tool for Managing Pancreatic Ductal Adenocarcinoma
Lead sponsor
Yingbin Liu, MD, PhD, FACS
Phase
Observational
Overall status
Recruiting
Start date
October 30, 2022
Completion date
July 22, 2026
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer, pancreatic neoplasm